$31.93 Million in Sales Expected for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) This Quarter

Equities analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAGet Rating) to announce sales of $31.93 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kiniksa Pharmaceuticals’ earnings, with the highest sales estimate coming in at $42.89 million and the lowest estimate coming in at $20.96 million. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Kiniksa Pharmaceuticals will report full-year sales of $119.15 million for the current financial year, with estimates ranging from $114.54 million to $123.76 million. For the next financial year, analysts anticipate that the business will post sales of $211.82 million, with estimates ranging from $199.05 million to $224.59 million. Zacks’ sales calculations are an average based on a survey of research firms that follow Kiniksa Pharmaceuticals.

Kiniksa Pharmaceuticals (NASDAQ:KNSAGet Rating) last issued its quarterly earnings results on Tuesday, February 22nd. The company reported ($0.53) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.09). The company had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $16.32 million.

Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Kiniksa Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 24th. Bank of America dropped their price target on Kiniksa Pharmaceuticals from $37.00 to $34.00 and set a “buy” rating on the stock in a research report on Wednesday, December 29th.

Several institutional investors have recently made changes to their positions in KNSA. Walleye Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals during the fourth quarter worth about $981,000. BlackRock Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 11.7% in the fourth quarter. BlackRock Inc. now owns 3,483,852 shares of the company’s stock valued at $41,007,000 after buying an additional 363,530 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Kiniksa Pharmaceuticals by 18.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 579,217 shares of the company’s stock valued at $6,817,000 after buying an additional 89,644 shares during the last quarter. Deutsche Bank AG increased its stake in shares of Kiniksa Pharmaceuticals by 1.6% during the fourth quarter. Deutsche Bank AG now owns 80,367 shares of the company’s stock worth $946,000 after purchasing an additional 1,255 shares during the period. Finally, California State Teachers Retirement System increased its stake in shares of Kiniksa Pharmaceuticals by 2.8% during the fourth quarter. California State Teachers Retirement System now owns 36,395 shares of the company’s stock worth $428,000 after purchasing an additional 989 shares during the period. Institutional investors own 43.01% of the company’s stock.

NASDAQ KNSA traded up $0.13 during trading on Wednesday, reaching $11.23. 123,255 shares of the company’s stock were exchanged, compared to its average volume of 325,620. Kiniksa Pharmaceuticals has a fifty-two week low of $9.05 and a fifty-two week high of $17.46. The company’s fifty day simple moving average is $10.46 and its 200-day simple moving average is $11.48.

About Kiniksa Pharmaceuticals (Get Rating)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Further Reading

Get a free copy of the Zacks research report on Kiniksa Pharmaceuticals (KNSA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.